This was the stock's 11th consecutive day of gains.

With an average analyst rating of buy, Humana is clearly an analyst favorite. But the analysts could be wrong. Is HUM overvalued at today's price of $243.33? Let's take a closer look at the ...

Humana (NYSE:HUM) has recently introduced Humana Healthy Horizons, a new Medicaid plan for Virginians under Cardinal Care, highlighting its focus on expanding in the Medicaid sector. This move ...

The S&P 500 added 0.5% on Wednesday, July 2, 2025, reaching a record-high close for the second time this week as the U.S.

Centene's stock plunged after slashing 2025 EPS guidance due to higher-than-expected morbidity and lower market growth in key ...

Shares of Humana Inc. (NYSE:HUM – Get Free Report) have received an average recommendation of “Hold” from the twenty-three ratings firms that are currently covering the firm, MarketBeat reports.

Healthcare Realty offers a 7-8% yield but faces rate pressures and tight dividend coverage. Learn why stabilization and ...

This was the stock's fourth consecutive day of gains.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Today, Zacks Equity Research discusses The Cigna Group CI, Humana Inc. HUM, Centene Corp. CNC and Molina Healthcare, Inc. MOH ...